June 17, 2022
According to the research report titled ‘Global Influenza Vaccines Market 2021 – 2027’, available with MarketStudyReport, global influenza vaccines market is slated to accrue a revenue of USD 6.5 billion during 2021-2027.
Numerous government initiatives for immunizing population against the illness, emergence of quadrivalent influenza vaccines, and widespread awareness about the disease are variables propelling the expansion of global influenza vaccines market.
Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3676278/
The document includes various factors that are boosting product demand as well as the constraints that are impeding industry growth during the forecast timeline. It summarizes the readily accessible expansion opportunities that can be used to generate substantial benefits in the years ahead.
The study also provides a comprehensive examination of the total vaccinated population around the world, as well as the most recent discoveries taking place in the business environment.
Experts cite that the number of people who have been inoculated against the influenza virus is likely to reach 500 million by the end of 2027.
An in-depth assessment on the geographical front is also included in the report on worldwide influenza vaccines industry to give a complete picture of the corporate environment.
Concerning regional aspect, the market spans across Asia Pacific (India, Australia, Japan, New Zealand, China), Latin America (Brazil), Europe (Netherlands, France, Italy, Ireland, Denmark, Germany, Sweden, Belgium, Poland, Spain, Finland, UK), and North America (Canada, U.S.).
Of these, China market is poised to amass USD 180 million by the end of the assessment timeframe, followed by United Kingdome, Germany, and Japan.
Further, a detailed examination of the competitive landscape reviews the significant players in the industry including Sanofi S.A., Pneumagen Limited, Shanghai Institute of Biological Products Co. Ltd., FluGen, Inc., Mylan N.V., AstraZeneca plc, Moderna, Inc., Novavax, Inc., Hualan Biological Engineering, Inc., BioDiem, Inc., Daiichi Sankyo Company Limited, CSL Limited, GlaxoSmithKline (GSK) plc, Altimmune, Inc., and Medicago, Inc. among others.
In the study of worldwide influenza vaccines market, aspects such as current vaccine portfolios, promising vaccines in clinical development, revenue share, sales value evaluation, and overall performance of the listed companies are illustrated for a deeper comprehension.